# Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

> **NCT05631886** · PHASE1 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Lymphoma
- EphA2 Overexpression
- TP53 R273H
- TP53 R175H
- TP53 R248Q
- TP53 R249S

## Interventions

- **BIOLOGICAL:** TP53-EphA-2-CAR-DC
- **DRUG:** Abraxane
- **DRUG:** Cyclophosphamide
- **DRUG:** anti-PD-1 antibody
- **DRUG:** Anti-CTLA4 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT05631886
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-04
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05631886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05631886, "Combination of CAR-DC Vaccine and ICIs in Malignant Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05631886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*